OTCMKTS:IPSEY - Ipsen Stock Price, Price Target & More

$38.65 -0.39 (-1.00 %)
(As of 04/25/2018 02:20 PM ET)
Previous Close$39.04
Today's Range$38.65 - $39.15
52-Week Range$26.94 - $39.86
Volume600 shs
Average Volume1,068 shs
Market Capitalization$13.07 billion
P/E RatioN/A
Dividend Yield0.45%
Beta-0.04

About Ipsen (OTCMKTS:IPSEY)

Ipsen logoIpsen S.A. operates as a pharmaceutical company worldwide. It operates in two segments, Primary Care and Specialty Care. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Decapeptyl, a synthetic hormone made of triptorelin and decapeptide analog of gonadotrophin releasing hormone, for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Hexvix, a photosensitizing agent, for detection and resection of non invasive bladder cancer. The company also provides Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Cometriq for medullary thyroid cancer; Dysport for motor disorders and muscular spasticity; NutropinAq, a liquid formulation, for treating growth failure in children due to growth hormone deficiency in adults; and Increlex used for long-term treatment of growth failure in children and adolescents. In addition, it offers Smecta, a formulation for use in the treatment of chronic and acute diarrhea; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults and children; and Tanaka for mild cognitive impairment related to age, pathophysiological deficiencies, vertigo, retinal deficits, acute or chronic hearing impairment, and tinnitus. Further, the company provides Adenuric for the treatment of gout; and Adrovance for treating post-menopausal osteoporosis. Additionally, it is developing chimeric somastatin and dopamine agonist molecule, VSN16R, OPS201, and OPS202 drugs, as well as botulinum toxin. Ipsen S.A. has a strategic agreement with Arix Bioscience plc to develop and commercialize various therapies. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

Receive IPSEY News and Ratings via Email

Sign-up to receive the latest news and ratings for IPSEY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:IPSEY
CUSIPN/A
Phone33-01-58-33-50-00

Debt

Debt-to-Equity RatioN/A
Current Ratio1.08%
Quick Ratio0.90%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E Ratio22.34
P/E Growth1.25

Sales & Book Value

Annual Sales$2.27 billion
Price / Sales5.69
Cash Flow$1.2651 per share
Price / Cash30.55
Book Value$5.19 per share
Price / Book7.45

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees4,907
Outstanding Shares334,770,000

How to Become a New Pot Stock Millionaire

Ipsen (OTCMKTS:IPSEY) Frequently Asked Questions

What is Ipsen's stock symbol?

Ipsen trades on the OTCMKTS under the ticker symbol "IPSEY."

How often does Ipsen pay dividends? What is the dividend yield for Ipsen?

Ipsen announced a None dividend on Friday, July 7th. Investors of record on Monday, June 12th will be given a dividend of $0.175 per share on Tuesday, July 11th. The ex-dividend date is Thursday, June 8th. View Ipsen's Dividend History.

Who are some of Ipsen's key competitors?

Who are Ipsen's key executives?

Ipsen's management team includes the folowing people:
  • Mr. David D. Meek, CEO & Director (Age 55)
  • Mr. Aymeric Le Chatelier, Exec. VP & CFO (Age 49)
  • Mr. Jonathan Henry Barnsley, Exec. Vice-Pres of Technical Operations (Age 61)
  • Dr. Alexandre P. LeBeaut M.D., Exec. VP of R&D and Chief Scientific Officer (Age 61)
  • Ms. Eugenia Litz, Vice-Pres of Investor Relations

Has Ipsen been receiving favorable news coverage?

Press coverage about IPSEY stock has trended positive recently, according to Accern Sentiment. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Ipsen earned a news impact score of 0.44 on Accern's scale. They also assigned news articles about the company an impact score of 47.82 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Ipsen?

Shares of IPSEY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ipsen's stock price today?

One share of IPSEY stock can currently be purchased for approximately $38.65.

How big of a company is Ipsen?

Ipsen has a market capitalization of $13.07 billion and generates $2.27 billion in revenue each year. The company earns $307.78 million in net income (profit) each year or $0.93 on an earnings per share basis. Ipsen employs 4,907 workers across the globe.

How can I contact Ipsen?

Ipsen's mailing address is 65 quai Georges Gorse, Boulogne-Billancourt cedex I0, 92650. The company can be reached via phone at 33-01-58-33-50-00 or via email at [email protected]


MarketBeat Community Rating for Ipsen (IPSEY)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  94 (Vote Outperform)
Underperform Votes:  79 (Vote Underperform)
Total Votes:  173
MarketBeat's community ratings are surveys of what our community members think about Ipsen and other stocks. Vote "Outperform" if you believe IPSEY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPSEY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ipsen (OTCMKTS:IPSEY) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Ipsen in the last 12 months. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Ipsen (OTCMKTS:IPSEY) Consensus Price Target History

Price Target History for Ipsen (OTCMKTS:IPSEY)

Ipsen (OTCMKTS:IPSEY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
9/20/2017Societe GeneraleUpgradeHold -> BuyView Rating Details
7/7/2016JPMorgan ChaseDowngradeOverweight -> NeutralView Rating Details
5/9/2016Morgan StanleyUpgradeEqual Weight -> OverweightView Rating Details
4/26/2016Jefferies GroupUpgradeHold -> BuyView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Dividends

Ipsen (OTCMKTS:IPSEY) Dividend Information

Ipsen pays an annual dividend of $0.17 per share, with a dividend yield of 0.44%. IPSEY's most recent none dividend payment was Tuesday, July 11. Ipsen pays out 18.28% of its earnings out as a dividend.
Most Recent Dividend:7/11/2017
Annual Dividend:$0.17
Dividend Yield:0.44%
Payout Ratio:18.28% (Trailing 12 Months of Earnings)
9.83% (Based on This Year's Estimates)
7.80% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Ipsen (OTCMKTS:IPSEY)

Ipsen (OTCMKTS:IPSEY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/7/2017None$0.17506/8/20176/12/20177/11/2017
(Data available from 1/1/2013 forward)

Insider Trades

Ipsen (OTCMKTS IPSEY) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 0.01%
Insider Trading History for Ipsen (OTCMKTS:IPSEY)

Ipsen (OTCMKTS IPSEY) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Ipsen (OTCMKTS IPSEY) News Headlines

Source:
DateHeadline
Analyzing Ipsen (IPSEY) and Its RivalsAnalyzing Ipsen (IPSEY) and Its Rivals
www.americanbankingnews.com - April 24 at 7:24 PM
Zacks Investment Research Lowers Ipsen (IPSEY) to HoldZacks Investment Research Lowers Ipsen (IPSEY) to Hold
www.americanbankingnews.com - April 24 at 11:34 AM
Comparing Ipsen (IPSEY) & Its CompetitorsComparing Ipsen (IPSEY) & Its Competitors
www.americanbankingnews.com - April 24 at 5:26 AM
Ipsen Announces Efficacy and Safety Data for Dysport® (abobotulinumtoxinA) Across Multiple Therapeutic Uses at the 2018 Annual Meeting of the American Academy of NeurologyIpsen Announces Efficacy and Safety Data for Dysport® (abobotulinumtoxinA) Across Multiple Therapeutic Uses at the 2018 Annual Meeting of the American Academy of Neurology
finance.yahoo.com - April 23 at 10:03 AM
Ipsen (IPSEY) vs. Its Peers Critical SurveyIpsen (IPSEY) vs. Its Peers Critical Survey
www.americanbankingnews.com - April 23 at 3:19 AM
Head-To-Head Contrast: Ipsen (IPSEY) and Its RivalsHead-To-Head Contrast: Ipsen (IPSEY) and Its Rivals
www.americanbankingnews.com - April 19 at 11:14 PM
Head to Head Comparison: Ipsen (IPSEY) vs. Its CompetitorsHead to Head Comparison: Ipsen (IPSEY) vs. Its Competitors
www.americanbankingnews.com - April 17 at 7:13 AM
Reviewing Ipsen (IPSEY) and The CompetitionReviewing Ipsen (IPSEY) and The Competition
www.americanbankingnews.com - April 16 at 5:19 PM
Ipsen (IPSEY) vs. Its Rivals Financial ReviewIpsen (IPSEY) vs. Its Rivals Financial Review
www.americanbankingnews.com - April 15 at 11:15 AM
Ipsen (IPSEY) Upgraded at Zacks Investment ResearchIpsen (IPSEY) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 14 at 8:35 PM
Financial Analysis: Ipsen (IPSEY) & Its CompetitorsFinancial Analysis: Ipsen (IPSEY) & Its Competitors
www.americanbankingnews.com - April 12 at 7:27 PM
Head-To-Head Review: Ipsen (IPSEY) versus Its CompetitorsHead-To-Head Review: Ipsen (IPSEY) versus Its Competitors
www.americanbankingnews.com - April 12 at 7:25 PM
Critical Contrast: Ipsen (IPSEY) and Its RivalsCritical Contrast: Ipsen (IPSEY) and Its Rivals
www.americanbankingnews.com - April 8 at 3:08 AM
IPSEN (IPSEY) and Its Rivals Critical ReviewIPSEN (IPSEY) and Its Rivals Critical Review
www.americanbankingnews.com - April 7 at 12:01 PM
Ipsen Announces EMA Validation of Filing of a New Application for Additional Indication for Cabometyx®, for Patients with Previously Treated Advanced Hepatocellular Carcinoma (HCC)Ipsen Announces EMA Validation of Filing of a New Application for Additional Indication for Cabometyx®, for Patients with Previously Treated Advanced Hepatocellular Carcinoma (HCC)
finance.yahoo.com - April 5 at 8:00 AM
Analyzing IPSEN (IPSEY) and The CompetitionAnalyzing IPSEN (IPSEY) and The Competition
www.americanbankingnews.com - April 3 at 5:04 PM
IPSEN (IPSEY) vs. Its Rivals Head-To-Head SurveyIPSEN (IPSEY) vs. Its Rivals Head-To-Head Survey
www.americanbankingnews.com - April 3 at 1:18 AM
IPSEN (IPSEY) Upgraded to "Buy" by Zacks Investment ResearchIPSEN (IPSEY) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - April 2 at 6:59 PM
Financial Review: Intellia Therapeutics (NTLA) & IPSEN (IPSEY)Financial Review: Intellia Therapeutics (NTLA) & IPSEN (IPSEY)
www.americanbankingnews.com - April 1 at 11:06 AM
EMA accepts Ipsens marketing application for Cabometyx for liver cancerEMA accepts Ipsen's marketing application for Cabometyx for liver cancer
seekingalpha.com - March 28 at 10:37 AM
Ipsen Receives Positive CHMP Opinion for Cabometyx® (cabozantinib) for the First-Line Treatment of Adults with Intermediate- or Poor- Risk Advanced Renal Cell CarcinomaIpsen Receives Positive CHMP Opinion for Cabometyx® (cabozantinib) for the First-Line Treatment of Adults with Intermediate- or Poor- Risk Advanced Renal Cell Carcinoma
finance.yahoo.com - March 23 at 6:33 PM
Ipsen Announces Health Canada Approval of DYSPORT THERAPEUTIC™ (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in AdultsIpsen Announces Health Canada Approval of DYSPORT THERAPEUTIC™ (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults
finance.yahoo.com - March 15 at 10:34 AM
Ipsen SA. (EPA:IPN): Will The Growth Last?Ipsen SA. (EPA:IPN): Will The Growth Last?
finance.yahoo.com - March 14 at 12:03 PM
Ipsen appoints Ivana Magovčević-Liebisch Ph.D., J.D. and Régis Mulot to Executive Leadership TeamIpsen appoints Ivana Magovčević-Liebisch Ph.D., J.D. and Régis Mulot to Executive Leadership Team
finance.yahoo.com - March 13 at 11:15 AM
Ipsen Announces 18 Posters to Be Presented at the 15th Annual ENETS ConferenceIpsen Announces 18 Posters to Be Presented at the 15th Annual ENETS Conference
finance.yahoo.com - March 6 at 4:03 PM
IPSEN (IPSEY) Raised to Buy at Zacks Investment ResearchIPSEN (IPSEY) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - February 25 at 2:18 PM
FY2019 Earnings Forecast for IPSEN Issued By Jefferies Group (IPSEY)FY2019 Earnings Forecast for IPSEN Issued By Jefferies Group (IPSEY)
www.americanbankingnews.com - February 22 at 2:46 PM
FY2018 EPS Estimates for IPSEN (IPSEY) Increased by AnalystFY2018 EPS Estimates for IPSEN (IPSEY) Increased by Analyst
www.americanbankingnews.com - February 21 at 11:35 AM
Arix Bioscience teams up with Ipsen to develop new therapiesArix Bioscience teams up with Ipsen to develop new therapies
seekingalpha.com - February 21 at 11:01 AM
Ipsen Announces Dysport® (abobotulinumtoxinA) Data Presentations Highlighting Duration of Response and Potential Benefit of Repeated Treatment in SpasticityIpsen Announces Dysport® (abobotulinumtoxinA) Data Presentations Highlighting Duration of Response and Potential Benefit of Repeated Treatment in Spasticity
finance.yahoo.com - February 15 at 3:49 PM
Ipsen Delivers Strong 2017 Results with 21.1%1 Sales Growth and Core Operating Margin Increase of 3.4 Points and Expects Significant Further Growth in Sales and Margin in 2018Ipsen Delivers Strong 2017 Results with 21.1%1 Sales Growth and Core Operating Margin Increase of 3.4 Points and Expects Significant Further Growth in Sales and Margin in 2018
finance.yahoo.com - February 15 at 9:25 AM
French pharma group Ipsen sees more asset purchases, U.S. growthFrench pharma group Ipsen sees more asset purchases, U.S. growth
finance.yahoo.com - February 15 at 9:25 AM
Health Canada approves Ipsens Somatuline® Autogel® for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs)Health Canada approves Ipsen's Somatuline® Autogel® for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs)
finance.yahoo.com - February 13 at 8:27 AM
IPSEN (IPSEY) to Release Quarterly Earnings on ThursdayIPSEN (IPSEY) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - February 9 at 12:16 AM
Ipsen Announces Eight Oral Presentations from Its Neurosciences Portfolio at the 10th World Congress for Neurorehabilitation (WCNR)Ipsen Announces Eight Oral Presentations from Its Neurosciences Portfolio at the 10th World Congress for Neurorehabilitation (WCNR)
finance.yahoo.com - February 7 at 8:30 AM
Ipsen to Present Data at ASCO GI 2018, Including New Post-Hoc Analyses from ONIVYDE® (irinotecan liposome injection) Phase 3 NAPOLI-1 TrialIpsen to Present Data at ASCO GI 2018, Including New Post-Hoc Analyses from ONIVYDE® (irinotecan liposome injection) Phase 3 NAPOLI-1 Trial
finance.yahoo.com - January 17 at 5:54 PM
EIGR Disappoints, EXELs CELESTIAL Excels, JUNO In CELGs Crosshairs?EIGR Disappoints, EXEL's CELESTIAL Excels, JUNO In CELG's Crosshairs?
www.nasdaq.com - January 17 at 8:50 AM
Exelixis, Ipsen report positive cancer-study resultsExelixis, Ipsen report positive cancer-study results
www.marketwatch.com - January 16 at 5:40 PM
Ipsen and Exelixis announce phase 3 trial results of cabozantinib demonstrating significant overall survival benefit in patients with previously treated advanced hepatocellular carcinomaIpsen and Exelixis announce phase 3 trial results of cabozantinib demonstrating significant overall survival benefit in patients with previously treated advanced hepatocellular carcinoma
finance.yahoo.com - January 16 at 5:40 PM
Ipsen Announces 13 Posters and 1 Oral Presentation at the 2018 ASCO Gastrointestinal SymposiumIpsen Announces 13 Posters and 1 Oral Presentation at the 2018 ASCO Gastrointestinal Symposium
finance.yahoo.com - January 15 at 5:43 PM
Ipsen Appoints Richard Paulson Executive Vice-President and Chief Executive Officer of Ipsen North AmericaIpsen Appoints Richard Paulson Executive Vice-President and Chief Executive Officer of Ipsen North America
finance.yahoo.com - January 12 at 9:11 AM
Ipsen Announces It is No Longer Eligible for the PEA-PME SchemeIpsen Announces It is No Longer Eligible for the PEA-PME Scheme
finance.yahoo.com - January 2 at 7:20 PM
IPSEN (IPSEY) Downgraded by Zacks Investment ResearchIPSEN (IPSEY) Downgraded by Zacks Investment Research
www.americanbankingnews.com - December 28 at 2:38 PM
Ipsen Announces Its Corporate Agenda for 2018Ipsen Announces Its Corporate Agenda for 2018
finance.yahoo.com - December 6 at 5:46 PM
Ipsen announces publication in Neurology of results of two studies demonstrating the efficacy and safety of Dysport® (abobotulinumtoxinA) in adult patients with lower limb spasticityIpsen announces publication in Neurology of results of two studies demonstrating the efficacy and safety of Dysport® (abobotulinumtoxinA) in adult patients with lower limb spasticity
finance.yahoo.com - November 29 at 9:04 AM
Ipsen Delivers Strong Sales Growth of 22.6%1 for the Third Quarter of 2017 and Confirms Full Year GuidanceIpsen Delivers Strong Sales Growth of 22.6%1 for the Third Quarter of 2017 and Confirms Full Year Guidance
finance.yahoo.com - October 26 at 2:30 PM
Ipsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular CarcinomaIpsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma
finance.yahoo.com - October 16 at 3:42 PM
Ipsen Announces Five Poster Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual AssemblyIpsen Announces Five Poster Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly
finance.yahoo.com - October 13 at 2:55 AM
Ipsen Joins PhRMA to Continue Advancing Research and InnovationIpsen Joins PhRMA to Continue Advancing Research and Innovation
finance.yahoo.com - October 11 at 4:43 PM
Ipsen Announces Four Poster Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 Child Neurology Society Annual MeetingIpsen Announces Four Poster Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 Child Neurology Society Annual Meeting
finance.yahoo.com - October 4 at 5:59 PM

SEC Filings

Ipsen (OTCMKTS:IPSEY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Ipsen (OTCMKTS IPSEY) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.